Actemra IV (tocilizumab) / Roche, JW Pharma - LARVOL DELTA

Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (clinicaltrials.gov) - P1/2 | N=10 | Enrolling by invitation | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Sep 2028 ➔ Sep 2029

Trial completion date • Immunology • Primary Immunodeficiency

Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase. (PubMed, Infect Dis Ther) - "These findings highlight the importance of continued pharmacovigilance and suggest potential CV safety differences among COVID-19 immunomodulators. Since tocilizumab and baricitinib are similarly indicated for severe patients with COVID-19, further clinical trials are warranted to explore whether tocilizumab represents a safer alternative to baricitinib for these patients. Insights from this study may guide future antiviral repurposing and pandemic preparedness strategies."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis

Tocilizumab as a treatment option in Sjögren disease with associated lymphocytic interstitial pneumonia. (PubMed, Clin Rheumatol) - No abstract available

Journal • Infectious Disease • Interstitial Lung Disease • Pneumonia • Respiratory Diseases • Sjogren's Syndrome

Efficacy and Safety of Tocilizumab Combined with Immunoglobulin in steroid-refractory/ resistant pneumonitis related to immune checkpoint blockade: A Retrospective Study (ESMO 2025) - No abstract available

Checkpoint block • Checkpoint inhibition • Retrospective data • Oncology

Tocilizumab for Lung Cancer-Associated Cachexia: A Multicenter, Single-Arm, Phase II Pilot Study (ESMO 2025) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Solid Tumor

GO40554: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=188 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Therapy Sequencing in Relapsed/Refractory MCL (ICML 2025) - P1, P1/2, P2, P3 | "Although a direct comparison between them has only been performed for ibrutinib and temsirolimus [23], covalent BTK inhibitor (cBTKi) single agent therapy has been consolidated as the standard of care after first-line CIT. Moreover, to address cBTKi failure, two anti-CD19 CAR-T cell therapy products, brexucabtagene autoleucel [20, 21] and lisocabtagene maraleucel [22], and the first noncovalent BTKi, pirtobrutinib [19], have recently been approved...Liso-cel only FDA approved; CIT, chemoimmunotherapy options include BR, R-BAC, R-CHOP, R-DHAP or R-DHAOx, R-GEMOx, paliative options (avoid bendamustine pre-CART apheresis); pirtobrutinib, available after cBTKi failure in second-line (EMA) but third-line (FDA); RM, rituximab maintenance...Orelabrutinib [18] is licensed only in China...Of note, both acalabrutinib and zanubrutinib induce lower rates of atrial fibrillation, hypertension, and bleeding compared to ibrutinib in randomized studies..."

IO biomarker • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology • PLCG2 • TP53

Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database. (PubMed, Mod Rheumatol) - "ObjectivesThe 2023 EULAR guidelines for systemic sclerosis (SSc) newly recommend biologics (rituximab, tocilizumab), mycophenolate mofetil (MMF), and nintedanib in addition to cyclophosphamide for interstitial lung disease (ILD)...For SSc, common first small-molecule drugs were methotrexate (24.2%), nintedanib (19.5%), tacrolimus (17.9%), and MMF (16.8%); common first biologics were rituximab (44.2%) and tocilizumab (29.1%)...Common subsequent treatments following rituximab or intravenous cyclophosphamide (which are typically administered for a limited duration) were nintedanib, MMF, and rituximab. ConclusionsRecent actual drug use in Japan has been aligning increasingly closely with the EULAR recommendations."

HEOR • Journal • Real-world evidence • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

TOXIC SYNERGY: A CASE OF COMBINED METHOTREXATE AND TOCILIZUMAB-INDUCED INTERSTITIAL LUNG DISEASE (CHEST 2025) - No abstract available

Clinical • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

USE OF TOCILIZUMAB FOR PULMONARY INVOLVEMENT IN VEXAS SYNDROME (CHEST 2025) - No abstract available

Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Best of Cell Therapy for Lymphoma: What We Learned in 2024 and 2025 (SOHO 2025) - P1/2, P2 | "Autologous CAR-T Therapy CD19 CAR-T New Regulatory Approvals In March 2024, the United States Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (lisocel) for relapsed/refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) after Bruton tyrosine kinase inhibitors (BTKis) and B-cell lymphoma 2 (BCL2) inhibitors, making it the first CAR-T approval in this disease...Long-Term Follow-up of Pivotal CD19 CAR-T Trials TRIAL (PRODUCT) LYMPHOMA SUBTYPE MEDIAN FU (MONTHS) ORR (%) CR (%) MEDIAN PFS (MONTHS) PFS (%) OS (%) NOTABLE SAFETY FINDINGS 64.6 90 75 (79% in FL cohort, 65% in MZL cohort) 62.2 53 (5 yr) 69 (5 yr) No new late signals ZUMA-5 (AXICEL) FL/MZL ( ≥ 3L) ELARA (TISA-CEL) FL ( ≥ 3L) 53 – * 69.1 53.3 50.2 (4 yr) 79.3 (4 yr) No new late signals; 6.2% secondary primary malignancies TRANSCEND FL (LISO-CEL) FL (2L+ high-risk/3L+) 29.5 – 30 95.7 – 97.1 94.2 – 95.7 NR 72.5 – 82.6 (2 yr) 88.2 –..."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Oncology • Peripheral T-cell Lymphoma • Small Lymphocytic Lymphoma • T Cell Non-Hodgkin Lymphoma • CD22 • CD5 • IL15 • TNFRSF8

Successful Treatment of Polyarteritis Nodosa With Multifocal Intracranial and Mesenteric Stenoses Using Endovascular Stenting and Tocilizumab. (PubMed, Cureus) - "Monthly tocilizumab induced rapid clinical and serological remission, sustained for 18 months. This case highlights that concomitant intracranial and mesenteric stenoses signal high-risk PAN. Additionally, deferring revascularisation until remission improves outcomes, and tocilizumab is a viable steroid-sparing option after cyclophosphamide failure, including cases of PAN with central nervous system involvement."

Journal • Ankylosing Spondylitis • Cardiovascular • Immunology • Inflammatory Arthritis • Ischemic stroke • Pain • Rheumatology • Seronegative Spondyloarthropathies • Vasculitis • IL6

GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - P3 | N=182 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2027 ➔ Sep 2027

Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1

Interleukin-6 Is a Potential Therapeutic Target in Refractory Immunotherapy-Mediated Cholangiopathy (ACG 2025) - "Her medical history is significant for stage IIIa chronic kidney disease and metastatic triple-negative breast cancer treated with bilateral mastectomy and adjuvant chemotherapy with 2 cycles of carboplatin, paclitaxel and pembrolizumab...Pembrolizumab was discontinued, and she was started on prednisone 80mg for presumed ICI hepatitis with adequate response. Despite steroids and mycophenolate mofetil (MMF), her labs again worsened (ALP 1138, AST 158, ALT 397, bilirubin 11.9)...Her bilirubin continued to rise despite treatment with high-dose prednisone, budesonide, ursodiol, and tacrolimus...IL-6 may serve as a biomarker predicting tocilizumab response with borderline elevation potentially being explained by steroid and tacrolimus administration. Further studies are warranted to establish diagnostic criteria and treatment strategies for this challenging irAE.Figure: Trends of Direct Bilirubin Over Time"

IO biomarker • Breast Cancer • Chronic Kidney Disease • Hepatology • Immunology • Infectious Disease • Nephrology • Renal Disease • Solid Tumor • Triple Negative Breast Cancer • IL6

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. (PubMed, Blood Cancer J) - "Among these, 1276 patients received BCMA BsAbs, 841 treated with GPRC5D/FcRH5 BsAbs, 157 received teclistamab + talquetamab, and 65 patients received a talquetamab + daratumumab, and 35 patients received talquetamab + pomalidomide...CRS and the need for tocilizumab were significantly less frequent with BCMA BsAbs vs GPRC5D/FcRH5 BsAbs, (P < 0.002)...GPRC5D/FcRH5 are associated with less grade 3/4 hematologic toxicity whereas BCMA BsAbs were associated with lower grade 3/4 CRS rates, compared to GPRC5D/FcRH5. These insights are crucial for guiding treatment decisions and developing strategies to improve patient outcomes."

Adverse events • Journal • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia

NP30179: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=920 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Aug 2027 ➔ Dec 2029 | Trial primary completion date: Aug 2027 ➔ Dec 2029

Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab. (PubMed, Clin Neurol Neurosurg) - "We present the case of a 54-year-old patient treated with cemiplimab, an immune checkpoint inhibitor (ICI), for multiple basal cell carcinomas in the context of Gorlin Goltz syndrome. Although guidelines exist for the acute treatment of a first relapse of ICI-induced NMOSD, long-term management to prevent new relapses remains challenging. We believe that these patients require maintenance therapy to prevent future relapses and propose rituximab or tocilizumab as suitable options."

Checkpoint inhibition • Journal • Basal Cell Carcinoma • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Non-melanoma Skin Cancer • Oncology • Rare Diseases

Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report. (PubMed, JTO Clin Res Rep) - "Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC."

Journal • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis. (PubMed, Hematol Oncol) - "To illustrate this issue, we introduce the case of a 68-year-old female with triple-class RRMM and end-stage renal disease requiring hemodialysis, treated with elranatamab as a second line treatment following progression after therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone. Despite experiencing grade I cytokine release syndrome during the initial administrations, symptoms were managed effectively with tocilizumab and dexamethasone, allowing treatment continuation...According to the literature, BCMA-directed immunotherapies, including teclistamab, belantamab mafodotin, and idecabtagene vicleucel, have shown efficacy in dialysis-dependent RRMM patients, though data remain limited...By providing real-world evidence for the use of bispecific antibodies in end stage renal disease patients, this review emphasizes the potential for expanding therapeutic options to this vulnerable population while highlighting the need for vigilant monitoring of infection..."

Journal • Chronic Kidney Disease • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Nephrology • Oncology • Renal Disease

Multi-Institution Analysis Evaluating Safety, Efficacy and ctDNA Dynamics Following Tarlatamab in ES-SCLC and LCNEC Patients (IASLC-WCLC 2025) - "CRS was observed in 56% of patients, all grade 1/2 in severity, with median onset within 24 hours following C1D1 and 44% requiring tocilizumab. However, in this non-trial setting, rates and timing of CRS/ICANS differed from previous reports, highlighting the need for careful observation and care coordination as this therapy is utilized in real-world practice. Novel biomarkers of response and resistance are needed in this setting, with longitudinal ctDNA dynamics showing potential promise, though larger, prospective studies are needed."

Circulating tumor DNA • Clinical • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Small Cell Lung Cancer • Solid Tumor • DLL3

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Hoffmann-La Roche | Initiation date: Sep 2024 ➔ Apr 2025

Trial initiation date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Daratumumab for Desensitization or Antibody-Mediated Rejection in Heart and Kidney Transplantation (WTC 2025) - "HLA Ab profiles were evaluated by Werfen single antigen bead assay, using 3000 MFI threshold (5000 MFI for DRB345, DQA, DPA, DPB) for cPRA.* One SHKTR and 2 HTRs (Patients (pts) 1-3) received a median (range) of 9 (8, 17) dara doses for AMR refractory to the following: Plasmapheresis (PLEX) and intravenous immunoglobulin (IVIg) plus bortezomib (BTZ), eculizumab or tocilizumab. Dara offers a promising approach for DES and rAMR. Addition of dara led to reduction in class I HLA Abs and modest reduction in class II HLA Abs. For AMR, longitudinal monitoring of ddcfDNA and MMDx showed improvement in allograft injury."

Antibody-mediated Rejection • Hematological Disorders • Infectious Disease • Thrombocytopenia • Transplantation

Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report. (PubMed, Transl Lung Cancer Res) - "He initially received pembrolizumab-based chemoimmunotherapy but developed grade 4 hepatitis, requiring immunosuppressive treatment and discontinuation of ICIs. The prophylactic use of agents like tocilizumab may reduce the risk of irAE recurrence. This underscores the need for individualized risk-benefit assessment and close clinical monitoring in rechallenge scenarios."

Checkpoint inhibition • IO biomarker • Journal • Tumor mutational burden • Endocrine Disorders • Inflammation • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TMB • TP53

A Strategy Utilizing Tocilizumab, Budesonide, and Mycophenolate Mofetil in the Peri-Operative Period to Achieve Biochemical Remission in High-Grade Immune Checkpoint Inhibitor-Mediated Cholangiohepatitis: A Case Study (ACG 2025) - "We present a case of ICI-mediated cholangiohepatitis (IMCH) with steroid-dependence successfully treated with tocilizumab combined with mycophenolate mofetil (MMF).Case Description/ A 53-year-old woman with a history of right breast cancer treated with neoadjuvant carboplatin/paclitaxel and an ICI, pembrolizumab, developed new-onset CTCAE grade 4 liver injury...After diagnostic liver biopsy confirmed IMCH, induction IV methylprednisolone (MP) 60 mg/d and IV tocilizumab (TCZ) 8 mg/kg were administered, but subsequent prednisone taper did not yield remission...Of note, although ursodeoxycholic acid was initially prescribed for the patient, she experienced gastrointestinal intolerance while taking it, so it was not utilized for the majority of the treatment course. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; CS, corticosteroids; MMF, mycophenolate mofetil; Pembro, pembrolizumab;..."

Case study • Checkpoint inhibition • Clinical • Breast Cancer • Hepatology • Liver Failure • Oncology • Solid Tumor • IL6

Multi-Institutional Real-World Experience of Early Tarlatamab-Related Toxicities for Extensive Stage Small Cell Lung Cancer (IASLC-WCLC 2025) - "No tocilizumab was required. This is the largest case series of Hispanic patients treated with tarlatamab. Future studies should refine toxicity mitigation protocols to enhance the safety and tolerability of tarlatamab in broader patient populations."

Clinical • Real-world • Real-world evidence • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3